Voyager Therapeutics, INC Form 4 insider transactions

Voyager Therapeutics reports the grant of stock options to Director George A. Scangos under the company's 2025 Stock Incentive Plan.

Voyager Therapeutics reports that Director Steven Hyman was granted 30,000 stock options under the company's 2025 Stock Incentive Plan.

Voyager Therapeutics reports the grant of stock options to Director Nancy Vitale under the company's 2025 Stock Incentive Plan.

Voyager Therapeutics, Inc. reports a stock option grant to Director Michael J. Higgins, exercisable at $3.43 with a 10-year expiration.

Voyager Therapeutics reports a Form 4 filing detailing the grant of stock options to Director Jude Onyia.

Voyager Therapeutics, Inc. reports that Director James A. Geraghty was granted stock options under the company's 2025 Stock Incentive Plan.

Voyager Therapeutics, Inc. reports a Form 4 filing detailing the grant of stock options to Director Grace Colon.

Voyager Therapeutics reports the grant of stock options to Director Glenn Pierce under the company's 2025 Stock Incentive Plan.

Voyager Therapeutics CEO Alfred Sandrock sold 11,511 shares of common stock for $3.87 per share, a transaction related to tax withholding obligations upon vesting of restricted stock units.

Voyager Therapeutics SVP and General Counsel Gregory L. Shiferman was granted 50,000 restricted stock units under the company's 2025 Stock Incentive Plan.

Voyager Therapeutics' COO and CBO, Robin Swartz, reported a non-discretionary sale of 6,458 common shares to cover tax withholding obligations related to RSU vesting.

Voyager Therapeutics CEO Alfred Sandrock sold 14,197 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Voyager Therapeutics' CFO, Nathan D. Jorgensen, sold 4,668 shares of common stock at a weighted average price of $3.77 to cover tax withholding obligations related to restricted stock unit vesting.

Voyager Therapeutics' Chief Scientific Officer, Todd Alfred Carter, sold 4,174 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Voyager Therapeutics' COO & CBO, Robin Swartz, sold 4,569 shares of common stock to cover tax withholding obligations related to RSU vesting.

Voyager Therapeutics' President and CEO, Alfred Sandrock, sold 12,192 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Voyager Therapeutics' Chief Scientific Officer, Todd Alfred Carter, sold 3,525 shares of common stock to cover tax withholding obligations related to RSU vesting.

Voyager Therapeutics' Chief Medical Officer, Toby Ferguson, received grants of 45,000 restricted stock units and options to purchase 210,000 shares of common stock.

Voyager Therapeutics' Chief Scientific Officer, Todd Alfred Carter, was granted 33,000 restricted stock units and options to purchase 154,000 shares of common stock.

Voyager Therapeutics, Inc. has awarded significant equity compensation to its Chief Operating Officer and Chief Business Officer, Robin Swartz.

Voyager Therapeutics' President and CEO, Alfred Sandrock, was granted 86,250 restricted stock units and 402,500 stock options.

Voyager Therapeutics' Chief Financial Officer, Nathan D. Jorgensen, was granted 32,250 restricted stock units and options to purchase 150,500 shares of common stock.

Voyager Therapeutics, Inc. granted its SVP and General Counsel, Gregory L. Shiferman, 100,000 stock options at an exercise price of $4.02 per share.

Voyager Therapeutics' Chief Financial Officer, Nathan D. Jorgensen, sold 7,666 shares of common stock to cover tax withholding obligations.

Voyager Therapeutics' Chief Medical Officer, Toby Ferguson, reported a planned sale of 19,000 shares of common stock under a 10b5-1 plan.

Voyager Therapeutics, Inc. Director Nancy Vitale was granted 24,000 stock options with an exercise price of $3.28, aligning her interests with shareholders.

Voyager Therapeutics, Inc. Director George A. Scangos was granted 24,000 stock options with an exercise price of $3.28, as part of the company's 2025 Stock Incentive Plan.

Voyager Therapeutics, Inc. Director Glenn Pierce was granted 24,000 stock options with an exercise price of $3.28 as part of the company's 2025 Stock Incentive Plan.

Voyager Therapeutics, Inc. director Jude Onyia was granted 24,000 stock options at an exercise price of $3.28, aligning his interests with long-term shareholder value.

Voyager Therapeutics, Inc. director Catherine J. Mackey was granted 24,000 stock options with an exercise price of $3.28, vesting upon the earlier of one year or the next annual meeting, as part of the company's 2025 Stock Incentive Plan.